NKX3.1 (NK3 homeobox 1) is a prostate tumour suppressor protein with a number of activities that are critical for its role in tumour suppression. NKX3.1 mediates the cellular response to DNA damage by interacting with ATM (ataxia telangiectasia mutated) and by activation of topoisomerase I. In the present study we characterized the interaction between NKX3.1 and topoisomerase I. The NKX3.1 homeodomain binds to a region of topoisomerase I spanning the junction between the core and linker domains. Loss of the topoisomerase I N-terminal domain, a region for frequent protein interactions, did not affect binding to NKX3.1 as was shown by the activation of Topo70 (N-terminal truncated topoisomerase I) in vitro. In contrast, NKX3.1 interacts with the enzyme reconstituted from peptide fragments of the core and linker active site domains, but inhibits the DNA-resolving activity of the reconstituted enzyme in vitro. The effect of NKX3.1 on both Topo70 and the reconstituted enzyme was seen in the presence and absence of camptothecin. Neither NKX3.1 nor CPT (camptothecin) had an effect on the interaction of the other with topoisomerase I. Therefore the interactions of NKX3.1 and CPT with the linker domain of topoisomerase I are mutually exclusive. However, in cells the effect of NKX3.1 on topoisomerase binding to DNA sensitized the cells to cellular toxicity and the induction of apoptosis by low doses of CPT. Lastly, topoisomerase I is important for the effect of NKX3.1 on cell survival after DNA damage as topoisomerase knockdown blocked the effect of NKX3.1 on clonogenicity after DNA damage. Therefore NKX3.1 and topoisomerase I interact in vitro and in cells to affect the CPT sensitivity and DNA-repair functions of NKX3.1.
Skip Nav Destination
Follow us on Twitter @Biochem_Journal
Article navigation
July 2013
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Research Article|
June 13 2013
Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I Available to Purchase
Liang-Nian Song;
Liang-Nian Song
1Departments of Medicine and Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 177 Ft. Washington Avenue, MHB 6N-435, New York, NY 10032, U.S.A.
Search for other works by this author on:
Cai Bowen;
Cai Bowen
1Departments of Medicine and Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 177 Ft. Washington Avenue, MHB 6N-435, New York, NY 10032, U.S.A.
Search for other works by this author on:
Edward P. Gelmann
Edward P. Gelmann
1
1Departments of Medicine and Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 177 Ft. Washington Avenue, MHB 6N-435, New York, NY 10032, U.S.A.
1To whom correspondence should be addressed (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
January 03 2013
Revision Received:
March 23 2013
Accepted:
April 05 2013
Accepted Manuscript online:
April 05 2013
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© The Authors Journal compilation © 2013 Biochemical Society
2013
Biochem J (2013) 453 (1): 125–136.
Article history
Received:
January 03 2013
Revision Received:
March 23 2013
Accepted:
April 05 2013
Accepted Manuscript online:
April 05 2013
Citation
Liang-Nian Song, Cai Bowen, Edward P. Gelmann; Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I. Biochem J 1 July 2013; 453 (1): 125–136. doi: https://doi.org/10.1042/BJ20130012
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() View past webinars > |